Mogamulizumab-Associated Kaposi Sarcoma in 2 Patients With Primary Cutaneous T-Cell Lymphomas

Key Points

• The report aims to highlight the occurrence of Kaposi sarcoma as a complication associated with mogamulizumab treatment in specific lymphoma patients.
• Case report on two patients experiencing treatment effects
• Clinical assessments documented under standard protocols
• Both patients developed Kaposi sarcoma following mogamulizumab treatment
• Findings suggest a potential link between immunotherapy and skin cancer development